BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 22306669)

  • 21. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
    Bisschop C; Ter Elst A; Bosman LJ; Platteel I; Jalving M; van den Berg A; Diepstra A; van Hemel B; Diercks GFH; Hospers GAP; Schuuring E
    Melanoma Res; 2018 Apr; 28(2):96-104. PubMed ID: 29232304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.
    Gonzalez D; Fearfield L; Nathan P; Tanière P; Wallace A; Brown E; Harwood C; Marsden J; Whittaker S
    Br J Dermatol; 2013 Apr; 168(4):700-7. PubMed ID: 23360189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultrasensitive detection and identification of BRAF V600 mutations in fresh frozen, FFPE, and plasma samples of melanoma patients by E-ice-COLD-PCR.
    How-Kit A; Lebbé C; Bousard A; Daunay A; Mazaleyrat N; Daviaud C; Mourah S; Tost J
    Anal Bioanal Chem; 2014 Sep; 406(22):5513-20. PubMed ID: 24969466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
    Yaman B; Kandiloğlu G; Akalin T
    Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
    Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
    Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
    Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
    Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
    Kim A; Cohen MS
    Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of BRAF V600 mutations in melanoma: evaluation of concordance between the Cobas® 4800 BRAF V600 mutation test and the methods used in French National Cancer Institute (INCa) platforms in a real-life setting.
    Mourah S; Denis MG; Narducci FE; Solassol J; Merlin JL; Sabourin JC; Scoazec JY; Ouafik L; Emile JF; Heller R; Souvignet C; Bergougnoux L; Merlio JP
    PLoS One; 2015; 10(3):e0120232. PubMed ID: 25789737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma.
    Lee S; Brophy VH; Cao J; Velez M; Hoeppner C; Soviero S; Lawrence HJ
    Virchows Arch; 2012 Feb; 460(2):141-9. PubMed ID: 22173329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low incidence of minor BRAF V600 mutation-positive subclones in primary and metastatic melanoma determined by sensitive and quantitative real-time PCR.
    Kristensen T; Clemmensen O; Hoejberg L
    J Mol Diagn; 2013 May; 15(3):355-61. PubMed ID: 23499336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF V600 mutations and pathological features in Japanese melanoma patients.
    Yamazaki N; Tanaka R; Tsutsumida A; Namikawa K; Eguchi H; Omata W; Oashi K; Ogawa T; Hayashi A; Nakamura N; Tsuta K
    Melanoma Res; 2015 Feb; 25(1):9-14. PubMed ID: 25051202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
    Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
    Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies.
    Lamy PJ; Castan F; Lozano N; Montélion C; Audran P; Bibeau F; Roques S; Montels F; Laberenne AC
    J Mol Diagn; 2015 Jul; 17(4):366-73. PubMed ID: 25952101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 36. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
    Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
    Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients.
    Barbano R; Pasculli B; Coco M; Fontana A; Copetti M; Rendina M; Valori VM; Graziano P; Maiello E; Fazio VM; Parrella P
    Sci Rep; 2015 Dec; 5():18592. PubMed ID: 26690267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
    Yang H; Higgins B; Kolinsky K; Packman K; Go Z; Iyer R; Kolis S; Zhao S; Lee R; Grippo JF; Schostack K; Simcox ME; Heimbrook D; Bollag G; Su F
    Cancer Res; 2010 Jul; 70(13):5518-27. PubMed ID: 20551065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma.
    Sener E; Yildirim P; Tan A; Gokoz O; Tezel GG
    Pathol Res Pract; 2017 May; 213(5):522-530. PubMed ID: 28216139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.